Article Search

Race, Rituxmab and relapse in TTP

Interesting food for thought in this ethnic group regarding TTP.  Large retrospective review of the TTP registry showing that among races there was no variation in mortality, however African-Americans had a reduced RFS in all metrics. Rituximab was not helpful in 1L therapy in any group.  In the 2L setting, Rituximab had a significant RFS benefit in Caucasians but not in African-Americans.  It did not seem that access to care was the driver in reduced RFS.  African-American’s may also have shorter-lived B-cell depletion from CD20-MAb therapy.

Read More »

Keyword Search

  • Cancer Types

  • Month Contributed

  • Show FCS Articles Only

  • Sort Order

  • Number of Posts